Transgenic gpt+ V79 cell lines differ in their mutagenic response to clastogens.
Several gpt+ transgenic cell lines were derived from hprt V79 cells to study mutagenesis mechanisms in mammalian cells. The G12 cell line was previously shown to be hypermutable by X-rays and UV at the gpt locus compared to the endogenous hprt gene of the parental V79 cells (Klein and Rossman, 1990), and is now shown to be highly mutable by the clastogenic anti-tumor agent bleomycin sulfate. A second transgenic cell line G10, which has a different gpt insertion site, was studied in comparison with G12. Both G12 and G10 cell lines carry the stable gpt locus at a single integration site in the Chinese hamster genome, and neither spontaneously deletes the integrated gpt sequence at a high frequency. Although spontaneous mutation to 6-thioguanine resistance in G10 cells is 3-4 times higher than in G12 cells, the cell lines differ to a much greater extent when mutated by clastogens. In comparison to G12 cells, the gpt locus in G10 cells is up to 13 times more sensitive to bleomycin mutagenesis and 5 times more responsive to X-ray mutagenesis. In contrast, there is much less difference in UV-induced mutagenesis and no differences in mutagenesis induced by alkylating agents such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). The dose-dependent decrease in survival of the transgenic cells is the same for all mutagens tested, and does not differ from that of V79 cells. Neither transgenic cell line is generally hypermutable, since mutagenesis at an endogenous gene, Na+K+/ATPase, is similar to that of the parental V79 cell line. Although both cell lines can be induced to delete the transgene following clastogen exposure, deletions are not the only recovered mutations, and the cell lines can also be used to study mutations within the PCR recoverable gpt gene. The utility of these transgenic cells to investigate genome position effects related to mammalian mutagenesis mechanisms is discussed.
Klein
C B
CB
Nelson Institute of Environmental Medicine, New York University Medical Center, A.J. Lanza Laboratory, Tuxedo 10987.
Su
L
L
Rossman
T G
TG
Snow
E T
ET
D000818:Animals; D030801:Animals, Genetically Modified; D001483:Base Sequence; D001761:Bleomycin / Q000633:toxicity; D002460:Cell Line / Q000187:drug effects / Q000528:radiation effects; D006224:Cricetinae; D003412:Cricetulus; D017931:DNA Primers; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004361:Drug Tolerance; D017353:Gene Deletion; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics*; D008769:Methylnitronitrosoguanidine / Q000633:toxicity; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009153:Mutagens / Q000633:toxicity; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011836:Radiation Tolerance; D000254:Sodium-Potassium-Exchanging ATPase / Q000235:genetics; D014466:Ultraviolet Rays
D017931:DNA Primers; D009153:Mutagens; D001761:Bleomycin; D008769:Methylnitronitrosoguanidine; D007041:Hypoxanthine Phosphoribosyltransferase; D000254:Sodium-Potassium-Exchanging ATPase